Zanamivir INN /zəˈnaemɨvɪər/ zəˈnæmɨvɪər is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by Influenza a And b. Viruses it was developed by The australian biotech Firm Biota. Holdings it was licensed To glaxo in 1990 and approved in THE us in, 1999 only for use as a treatment for. influenza In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.